-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis doses first patient in global Phase III trials of oral GLP-1 ASC30 for weight management

PUBT·08/31/2026 07:06:04
Listen to the news
Ascletis doses first patient in global Phase III trials of oral GLP-1 ASC30 for weight management
  • Ascletis dosed the first participant in a global Phase III program for ASC30, a once-daily oral GLP-1 drug for chronic weight management.
  • Results have not been presented; topline data are expected in Q3 2028, ahead of planned US filing by end-2028.
  • Program targets long-term weight management in people with obesity or overweight, including separate studies for patients with type 2 diabetes.
  • Trials aim to confirm ASC30’s efficacy, safety, and tolerability to support potential entry as an oral alternative to injectable obesity therapies.
  • Enrollment is expected to reach about 4,600 participants across the US, Europe, and Canada.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608300615PR_NEWS_USPR_____CN36570) on August 30, 2026, and is solely responsible for the information contained therein.